Clinical Study
A Flow Cytometric Analysis of Vitreous Inflammatory Cells in Patients with Proliferative Diabetic Retinopathy
Table 3
Paired comparison of vitreous and blood samples in patients with PDR (median, minimum–maximum; Wilcoxon signed rank test).
| | | Patients with PDR () | | | Vitreous | Blood | P value |
| | CD45+ (number) | 648.0 (181.0–4926.0) | 106869.5 (85539.0–265227.0) | 0.0001 | | Ly (%) | 9.9 (0.4–89.6) | 26.8 (8.5–82.1) | 0.158 | | CD14+ (%) | 62.1 (5.3–87.7) | 5.5 (1.2–12.0) | 0.0001 | | CD19+ (%) | 0 (0–9.7) | 8.9 (2.5–83.0) | 0.0001 | | CD3+ (%) | 82.4 (0–100.0) | 71.0 (12.6–95.6) | 0.362 | | CD3/CD19 | 83.5 (14.1–100.0) | 8.2 (3.1–27.0) | 0.0001 | | CD4+ (%) | 75.9 (0–100.0) | 62.4 (24.7–78.4) | 0.452 | | CD8+ (%) | 14.0 (0–66.7) | 33.1 (16.9–68.2) | 0.0001 | | CD4/CD8 | 4.3 (0.5–100.0) | 1.9 (0.4–23.0) | 0.003 |
|
|
Legend: PDR: proliferative diabetic retinopathy; CD45+: leukocytes; Ly: lymphocytes; CD14+: macrophages; CD19+: B lymphocytes; CD3+: T lymphocytes; CD4+: T helper lymphocytes; CD8+: T cytotoxic lymphocytes.
|
